A new study being led by the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, and University College London aims to explore the immune response to natural COVID-19 infection and vaccination in patients with antibody def
Share This
The FINANCIAL COVID infection in patients with antibody deficiency (COVAD) is part of a portfolio of national studies examining the immune responses in patients at high risk of COVID-19.
A new study, funded by UK Research and Innovation, aims to explore the immune response to natural COVID-19 infection and vaccination in patients with antibody deficiency. The study is being led by:
University of Birmingham
University College London.
Vulnerable patients
Immunodeficiency patients are considered vulnerable or extremely vulnerable to COVID-19 infection and have had to undertake preventative measures to minimise their risk of exposure to the virus according to UKRI.